PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsIpilimumab
Yervoy(ipilimumab)
Yervoy (ipilimumab) is an antibody pharmaceutical. Ipilimumab was first approved as Yervoy on 2011-03-25. It is used to treat melanoma in the USA. It has been approved in Europe to treat colorectal neoplasms, malignant mesothelioma, melanoma, non-small-cell lung carcinoma, and renal cell carcinoma. The pharmaceutical is active against cytotoxic T-lymphocyte protein 4.
Download report
Favorite
Drugs Approved for Childhood Cancers
BMS
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
Trade Name
FDA
EMA
Yervoy
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Ipilimumab
Tradename
Proper name
Company
Number
Date
Products
YervoyipilimumabBristol Myers SquibbN-125377 RX2011-03-25
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
yervoyBiologic Licensing Application2025-05-28
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
melanomaD008545
Agency Specific
FDA
EMA
Expiration
Code
ipilimumab, Yervoy, Bristol-Myers Squibb Company
2027-10-02Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01F: Monoclonal antibodies and antibody drug conjugates
L01FX: Other monoclonal antibodies and antibody drug conjugates in atc
L01FX04: Ipilimumab
HCPCS
Code
Description
J9228
Injection, ipilimumab, 1 mg
Clinical
Clinical Trials
904 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal cell carcinomaD002292EFO_000037621541627
Lung neoplasmsD008175C34.907931218
Kidney neoplasmsD007680EFO_0003865C64221128
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanomaD00854531551223111
NeoplasmsD009369C8026371147
Non-small-cell lung carcinomaD00228911247640
Prostatic neoplasmsD011471C61318321
Neoplasm metastasisD009362EFO_0009708710216
Colorectal neoplasmsD01517969112
Small cell lung carcinomaD05575238110
Brain neoplasmsD001932EFO_0003833C7127110
CarcinomaD002277C80.033159
Liver neoplasmsD008113EFO_1001513C22.05428
Show 8 more
Indications Phases 2
Indications Phases 1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis cD006526B19.211
Hepatitis bD00650911
HepatitisD006505K75.911
Hepatitis aD006506EFO_0007305B1511
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIpilimumab
INNipilimumab
Description
Ipilimumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>7SU0:H,I|Fab heavy chain (PCA)VQLVESGGGVVQPGRSLRLSCAASGFTFSHYTMHWVRQAPGKGLEWVTFISYDGHNKYYADSVKGRFTISRDNSK NTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCGGHHHHHH >7SU0:L,M|Fab light chain EIVLTQSPGTLSLSPGERATLSCRASQEVGESELAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLE PEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB5TRU, 5XJ3, 6JC2, 6RP8, 7SU0, 7SU1
CAS-ID
RxCUI
ChEMBL IDCHEMBL1789844
ChEBI ID
PubChem CID
DrugBankDB06186
UNII ID6T8C155666 (ChemIDplus, GSRS)
Target
Agency Approved
CTLA4
CTLA4
Organism
Homo sapiens
Gene name
CTLA4
Gene synonyms
CD152
NCBI Gene ID
Protein name
cytotoxic T-lymphocyte protein 4
Protein synonyms
CD152, celiac disease 3, CTLA-4, cytotoxic T lymphocyte associated antigen 4 short spliced form, Cytotoxic T-lymphocyte-associated antigen 4, cytotoxic T-lymphocyte-associated serine esterase-4, gluten-sensitive enteropathy, insulin-dependent diabetes mellitus 12, ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
Uniprot ID
Mouse ortholog
Ctla4 (12477)
cytotoxic T-lymphocyte protein 4 (P09793)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
£
Yervoy Bristol Myers Squibb
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 50,703 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
39,766 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use